Cardiovascular Therapeutic Drugs Market - Size, Share and Forecast (2019-2026)

SKU: DHC265 | Last Updated On: 2019-08-12 | No. of Pages: 217 | Available Formats

( 43 Samples have been requested. )
In May 2019, the U.S. FDA approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy).

Cardiovascular Therapeutic Drugs Market Overview

The cardiovascular diseases (CVDs) therapeutic drugs are used to treat several disorders of the heart and blood vessels such as coronary artery disease, arrhythmias, and heart defects, among others. The global cardiovascular therapeutic drugs market size was worth $ XX billion in 2018 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period (2019-2026).

Cardiovascular Therapeutic Drugs Market Dynamics

The cardiovascular therapeutic drugs market growth is driven by rising prevalence of cardiovascular diseases globally, growing elderly population, and increasing development of new drugs for the treatment of CVDs.

According to the World Health Organization (WHO), in 2017, CVD is the number 1 cause of death globally. In 2016, an estimated 17.9 million people died from CVDs, representing 31% of all global deaths. Of these deaths, 85% are due to heart attack and stroke. Over three quarters of CVD deaths take place in low- and middle-income countries. Out of the 17 million premature deaths (under the age of 70) due to non-communicable diseases in 2015, 82% are in low- and middle-income countries, and 37% are caused by CVDs.  For the treatment of these diseases, manufacturers are highly investing to develop new drugs with better efficacy and low side effects. For instance, in February 2019, Novartis and Blackstone’s Life Sciences launched Anthos Therapeutics focusing on high-risk cardiovascular patients. Blackstone is investing $250 million, while Novartis is licensing MAA868, a drug for patients who are underserved by existing anti-coagulant drugs.

However, high investment cost and recent expiry of patent exclusivity of cardiovascular drugs are some of the factors hampering the growth of the global cardiovascular drugs market. For instance, in July 2015, Novartis set a price of $4,560 a year for its new heart failure pill Entresto, nearly 50% higher than expected. From 2012 to 2015, nitroprusside prices increased 30-fold from $27.46 to $880.88, while isoproterenol prices increased nearly 70-fold from $26.20 to $1,790.11. These medications are used only in the hospital, with no external patient demand.

There are several drugs in the pipeline for the treatment of various cardiovascular diseases. For instance, Revascor is a Phase III product candidate being developed as a treatment for both advanced and end-stage chronic heart failure (CHF). It is currently the most advanced regenerative therapy in development for heart failure.

SAR440181 is a myosin activator, a new small molecule entity that is administered orally and is currently in Phase II trials. The drug was developed based on MyoKardia’s precision medicine platform, which the company utilizes to develop therapies for rare cardiovascular diseases.

There are several unmet needs in cardiovascular drugs market globally which creates large number of opportunities for existing market players and new entrants in the market. For instance, Biologics provide large opportunities for players operating in the cardiovascular drugs market. Recent developments in biologic cardiovascular drugs such as Merck’s CETP inhibitor anacetrapib, Pfizer’s PCSK9 inhibitor, and Esperion Therapeutics’ novel LDL-lowering drug ETC-1002, uncover the potential of these drugs. Some drugs are losing their patent which leads to introduce generics in market by local as well as international players. For instance, in early 2016, Astrazeneca launched Crestor for the treatment of hyperlipidemia, lost patent in and in April 2016, the U.S. FDA approved first generic to this drug to Watson Pharmaceuticals Inc.

Cardiovascular Therapeutic Drugs Market Segment Analysis

By drug class, the global cardiovascular therapeutic drugs market is segmented into Anti hyperlipidemias, Anti-hypertensives, Anti-coagulants, Anti-fibrinolytics, Anti-arrhythmic, and Others. Among these, anti-coagulants drug class is projected to account for the largest market share during the forecast period, followed by anti-hyperlipidemia segment. The rising incidence of hyperlipidemia and introduction of new anti-hyperlipidemia drug are driving the growth of the segment. Hyperlipidemia involves an imbalance of cholesterol levels, including low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) in the blood. LDL-C and HDL-C regulate the amount of cholesterol in the body and an imbalance can increase the risk of cardiovascular events, including myocardial infarction and stroke. According to CDC, in 2015–2016, more than 12% of adults age 20 and older had total cholesterol higher than 240 mg/dL, and more than 18% had high-density lipoprotein (HDL, or “good”) cholesterol levels less than 40 mg/dL. Launch of PCSK9 inhibitors (Praluent) for treating hyperlipidemia in 2016 is likely to fuel expansion of anti-hyperlipidemia drugs market segment by 2025 augmenting global cardiovascular drugs market.

On the basis of diseases, the market is segmented into cardiac arrhythmias, hypertension, arteriosclerosis, acute coronary syndrome, myocardial infarction, peripheral artery disease, coronary artery disease, cardiac failure diseases, thrombosis, hyperlipidemia, and others. Among these, hypertension held the largest market share in 2018 and likely to grow at a significant CAGR during the forecast period.  However, Arrhythmia segment is expected to hold low market share during the forecast period due to shift of preference from anti-arrhythmia drugs to advanced implantable cardiovascular devices such as pacemakers. According to the American Heart Association data, 2019, from 2013-2016, 46.0% of US adults had hypertension. In 2016, there were 82,735 deaths primarily attributable to High Blood Pressure. In 2016, the age-adjusted death rate primarily attributable to high blood pressure was 21.6 per 100,000.  Projections show that by 2035, the total direct costs of High Blood Pressure could increase to an estimated $220.9 billion.

Cardiovascular Therapeutic Drugs Market Geographical Analysis

North America is dominating the Cardiovascular Therapeutic Drugs market in 2018 and estimated to hold largest market size over the forecast period (2019-2026), owing to the rising prevalence of cardiovascular disease and introduction of new drugs for the treatment. Cardiovascular disease (CVD), is one of the major cause of death, accounted for 840,678 deaths in the US in 2016, approx. 1 of every 3 deaths. Between 2013 and 2016, 121.5 million American adults had some form of cardiovascular disease. As per the American Heart Association, 2019, 116.4 million or 46% of the US adults are estimated to have hypertension. In 2016, Coronary Heart Disease was the leading cause (43.2%) of deaths attributable to cardiovascular disease in the US, followed by stroke (16.9%), High Blood Pressure (9.8%), Heart Failure (9.3%), diseases of the arteries (3.0%), and other cardiovascular diseases (17.7%). The players are investing high on the new drug development for the treatment of cardiovascular diseases in this region. For instance, in February 2019, Novartis and Blackstone’s Life Sciences launched Anthos Therapeutics focusing on high-risk cardiovascular patients. Blackstone is investing $250 million, while Novartis is licensing MAA868, a drug for patients who are underserved by existing anti-coagulant drugs.

Cardiovascular Therapeutic Drugs Market Competitive Landscape

The Cardiovascular Therapeutic Drugs market is dominated by few major players including Biophan Technologies, Berlin Heart GmbH, Calon Cardio-Technology Ltd., MAQUET GmbH & Co., Teleflex Incorporated, Heart Ware International, Abiomed Inc., Thoratec Corporation, SynCardia Systems, and Bioheart. The players are focusing on product approvals and developing innovative products to strengthen their product portfolio that intensifies the market competition. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the Cardiovascular Therapeutic Drugs market globally. For instance,

In May 2019, the U.S. FDA approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults.

In March 2019, Baxter International Inc. launched the U.S. Food and Drug Administration (FDA) approved ready-to-use eptifibatide. Baxter’s presentation of eptifibatide is the first of its kind available in a flexible container.

In February 2019, Novartis and Blackstone’s Life Sciences launched Anthos Therapeutics focusing on high-risk cardiovascular patients. Blackstone is investing $250 million, while Novartis is licensing MAA868, a drug for patients who are underserved by existing anti-coagulant drugs.

In August 2018, Medicure Inc., a cardiovascular pharmaceutical company, received the U.S. FDA approval for its Abbreviated New Drug Application ("ANDA") for Sodium Nitroprusside Injection 50 mg/2 mL (25 mg/mL) single dose vial ("SNP"), a generic intravenous cardiovascular drug product. 

In December 2017, Amgen received the U. S. FDA approval for Repatha® (evolocumab), the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularizations in adults with established cardiovascular disease.

Why Purchase the Report?

  • Visualize the composition of the cardiovascular therapeutic drugs in terms of types of drugs for various cardiovascular diseases highlighting the key commercial assets and players.
  • Identify commercial opportunities in cardiovascular therapeutic drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of cardiovascular therapeutic drugs market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Global Cardiovascular Therapeutic Drugs Market

  1. Global Cardiovascular Therapeutic Drugs Market Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Global Cardiovascular Therapeutic Drugs Market – Market Definition and Overview

  3. Global Cardiovascular Therapeutic Drugs Market – Executive Summary

    1. Market Snippet by Drug Class
    2. Market Snippet by Disease
    3. Market Snippet by Distribution Channel
  4. Global Cardiovascular Therapeutic Drugs Market – Market Dynamics

    1. Market Impacting Factors
    2. Drivers
      1. Rising Prevalence of Heart Failure
      2. Increasing Technological Advancement in Devices
    3. Restraints
      1. High Cost of Cardiovascular Therapeutic Drugs
    4. Opportunity
    5. Impact Analysis
  5. Global Cardiovascular Therapeutic Drugs Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Regulatory Analysis
    3. Supply Chain Analysis
    4. Pricing Analysis
  6. Global Cardiovascular Therapeutic Drugs Market – By Drug class

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
    3. Market Attractiveness Index, By Drug Class Segment
    4. Anti-hypertensives*
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    5. Anti-hyperlipidemias
    6. Anti-arrhythmic
    7. Anti-coagulants
    8. Anti-fibrinolytics
    9. Others
  7. Global Cardiovascular Therapeutic Drugs Market – By Disease

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Segment
    3. Market Attractiveness Index, By Disease Segment
      1. Hypertension 
        1. Introduction
        2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
      2. Cardiac arrhythmias 
      3. Arteriosclerosis 
      4. Acute Coronary Syndrome
      5. Myocardial infarction 
      6. Peripheral artery disease 
      7. Coronary artery disease 
      8. Cardiac failure diseases 
      9. Thrombosis
      10. Hyperlipidemia 
      11. Others
  8. Global Cardiovascular Therapeutic Drugs Market – By Distribution Channel

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    3. Market Attractiveness Index, By Distribution Channel Segment
      1. Hospitals Pharmacies*
        1. Introduction
        2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
  9. Global Cardiovascular Therapeutic Drugs Market – By Region

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  10. Global Cardiovascular Therapeutic Drugs Market – Competitive Landscape

    1. Competitive Scenario
    2. Market Positioning/Share Analysis
    3. Mergers and Acquisitions Analysis
  11. Company Profiles

    1. Abbott Laboratories.*
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. AstraZeneca
    3. Pfizer Inc
    4. Novartis
    5. Bristol Myer Squibb
    6. Bayer
    7. Merck
    8. Sanofi
    9. Boehringer Ingelhein
    10. Roche
  12. Global Cardiovascular Therapeutic Drugs Market – Premium Insights

  13. Global Cardiovascular Therapeutic Drugs Market – DataM

    1. Appendix
    2. About Us and Services
    3. Contact Us

List of Tables

Table 1 Global Cardiovascular Therapeutic Drugs Market Value, By Drug Class, 2018,2022 & 2026 ($ Million)

Table 2 Global Cardiovascular Therapeutic Drugs Market Value, By Disease, 2018,2022 & 2026 ($ Million)

Table 3 Global Cardiovascular Therapeutic Drugs Market Value, By Distribution Channel, 2018,2022 & 2026 ($ Million)

Table 4 Global Cardiovascular Therapeutic Drugs Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 5 Global Cardiovascular Therapeutic Drugs Market Value, By Drug Class, 2018,2022 & 2026 ($ Million)

Table 6 Global Cardiovascular Therapeutic Drugs Market Value, By Drug Class, 2017-2026 ($ Million)

Table 7 Global Cardiovascular Therapeutic Drugs Market Value, By Disease, 2018,2022 & 2026 ($ Million)

Table 8 Global Cardiovascular Therapeutic Drugs Market Value, By Disease, 2017-2026 ($ Million)

Table 9 Global Cardiovascular Therapeutic Drugs Market Value, By Distribution Channel, 2018,2022 & 2026 ($ Million)

Table 10 Global Cardiovascular Therapeutic Drugs Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 11 Global Cardiovascular Therapeutic Drugs Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 12 Global Cardiovascular Therapeutic Drugs Market Value, By Region, 2017-2026 ($ Million)

Table 13 North America Cardiovascular Therapeutic Drugs Market Value, By Drug Class, 2017-2026 ($ Million)

Table 14 North America Cardiovascular Therapeutic Drugs Market Value, By Disease, 2017-2026 ($ Million)

Table 15 North America Cardiovascular Therapeutic Drugs Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 16 North America Cardiovascular Therapeutic Drugs Market Value, By Country, 2017-2026 ($ Million)

Table 17 South America Cardiovascular Therapeutic Drugs Market Value, By Drug Class, 2017-2026 ($ Million)

Table 18 South America Cardiovascular Therapeutic Drugs Market Value, By Disease, 2017-2026 ($ Million)

Table 19 South America Cardiovascular Therapeutic Drugs Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 20 South America Cardiovascular Therapeutic Drugs Market Value, By Country, 2017-2026 ($ Million)

Table 21 Europe Cardiovascular Therapeutic Drugs Market Value, By Drug Class, 2017-2026 ($ Million)

Table 22 Europe Cardiovascular Therapeutic Drugs Market Value, By Disease, 2017-2026 ($ Million)

Table 23 Europe Cardiovascular Therapeutic Drugs Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 24 Europe Cardiovascular Therapeutic Drugs Market Value, By Country, 2017-2026 ($ Million)

Table 25 Asia-Pacific Cardiovascular Therapeutic Drugs Market Value, By Drug Class, 2017-2026 ($ Million)

Table 26 Asia-Pacific Cardiovascular Therapeutic Drugs Market Value, By Disease, 2017-2026 ($ Million)

Table 27 Asia-Pacific Cardiovascular Therapeutic Drugs Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 28 Asia-Pacific Cardiovascular Therapeutic Drugs Market Value, By Country, 2017-2026 ($ Million)

Table 29 Middle East & Africa Cardiovascular Therapeutic Drugs Market Value, By Drug Class, 2017-2026 ($ Million)

Table 30 Middle East & Africa Cardiovascular Therapeutic Drugs Market Value, By Disease, 2017-2026 ($ Million)

Table 31 Middle East & Africa Cardiovascular Therapeutic Drugs Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 32 Abbott Laboratories: Overview

Table 33 Abbott Laboratories: Product Portfolio

Table 34 Abbott Laboratories: Key Developments

Table 35 Pfizer Inc.: Overview

Table 36 Pfizer Inc.: Product Portfolio

Table 37 Pfizer Inc.: Key Developments

Table 38 AstraZeneca plc.: Overview

Table 39 AstraZeneca plc.: Product Portfolio

Table 40 AstraZeneca plc.: Key Developments

Table 41 Novartis AG: Overview

Table 42 Novartis AG: Product Portfolio

Table 43 Novartis AG: Key Developments

Table 44 Bristol-Myers Squibb Company: Overview

Table 45 Bristol-Myers Squibb Company: Product Portfolio

Table 46 Bristol-Myers Squibb Company: Key Developments

Table 47 Bayer AG: Overview

Table 48 Bayer AG: Product Portfolio

Table 49 Bayer AG: Key Developments

Table 50 Merck & Co., Inc.: Overview

Table 51 Merck & Co., Inc.: Product Portfolio

Table 52 Merck & Co., Inc.: Key Developments

Table 53 Sanofi: Overview

Table 54 Sanofi: Product Portfolio

Table 55 Sanofi: Key Developments

Table 56 Boehringer Ingelheim GmbH: Overview

Table 57 Boehringer Ingelheim GmbH: Product Portfolio

Table 58 Boehringer Ingelheim GmbH: Key Developments

Table 59 F. Hoffmann-La Roche Ltd: Overview

Table 60 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 61 F. Hoffmann-La Roche Ltd: Key Developments

 List of Figures

Figure 1 Global Cardiovascular Therapeutic Drugs Market Share, By Drug Class, 2018 & 2026 (%)

Figure 2 Global Cardiovascular Therapeutic Drugs Market Share, By Disease, 2018 & 2026 (%)

Figure 3 Global Cardiovascular Therapeutic Drugs Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 4 Global Cardiovascular Therapeutic Drugs Market Share, By Region, 2018 & 2026 (%)

Figure 5 Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 6 Global Cardiovascular Therapeutic Drugs Market Y-o-Y Growth, By Drug Class, 2018-2026 (%)

Figure 7 Anti-hypertensives: Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 8 Anti-hyperlipidemia: Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 9 Anti-arrhythmic: Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 10 Anti-coagulants: Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 11 Anti-fibrinolytics: Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 12 Global Cardiovascular Therapeutic Drugs Market Y-o-Y Growth, By Disease, 2018-2026 (%)

Figure 13 Cardiac arrhythmias : Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 14 Hypertension : Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 15 Arteriosclerosis : Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 16 Acute Coronary Syndrome: Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 17 Myocardial infarction : Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 18 Peripheral artery disease : Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 19 Coronary artery disease : Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 20 Others: Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 21 Global Cardiovascular Therapeutic Drugs Market Y-o-Y Growth, By Distribution Channel, 2018-2026 (%)

Figure 22 Hospital Pharmacies: Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 23 Retail Pharmacies: Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 24 Online Pharmacies: Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 25 Others: Global Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 26 Global Cardiovascular Therapeutic Drugs Market Y-o-Y Growth, By Region, 2018-2026 (%)

Figure 27 North America Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 28 North America Cardiovascular Therapeutic Drugs Market Share, By Drug Class, 2018 & 2026 (%)

Figure 29 North America Cardiovascular Therapeutic Drugs Market Share, By Disease, 2018 & 2026 (%)

Figure 30 North America Cardiovascular Therapeutic Drugs Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 31 North America Cardiovascular Therapeutic Drugs Market Share, By Country, 2018 & 2026 (%)

Figure 32 South America Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 33 South America Cardiovascular Therapeutic Drugs Market Share, By Drug Class, 2018 & 2026 (%)

Figure 34 South America Cardiovascular Therapeutic Drugs Market Share, By Disease, 2018 & 2026 (%)

Figure 35 South America Cardiovascular Therapeutic Drugs Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 36 South America Cardiovascular Therapeutic Drugs Market Share, By Country, 2018 & 2026 (%)

Figure 37 Europe Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 38 Europe Cardiovascular Therapeutic Drugs Market Share, By Drug Class, 2018 & 2026 (%)

Figure 39 Europe Cardiovascular Therapeutic Drugs Market Share, By Disease, 2018 & 2026 (%)

Figure 40 Europe Cardiovascular Therapeutic Drugs Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 41 Europe Cardiovascular Therapeutic Drugs Market Share, By Country, 2018 & 2026 (%)

Figure 42 Asia-Pacific Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 43 Asia-Pacific Cardiovascular Therapeutic Drugs Market Share, By Drug Class, 2018 & 2026 (%)

Figure 44 Asia-Pacific Cardiovascular Therapeutic Drugs Market Share, By Disease, 2018 & 2026 (%)

Figure 45 Asia-Pacific Cardiovascular Therapeutic Drugs Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 46 Asia-Pacific Cardiovascular Therapeutic Drugs Market Share, By Country, 2018 & 2026 (%)

Figure 47 Middle East & Africa Cardiovascular Therapeutic Drugs Market Value, 2017-2026 ($ Million)

Figure 48 Middle East & Africa Cardiovascular Therapeutic Drugs Market Share, By Drug Class, 2018 & 2026 (%)

Figure 49 Middle East & Africa Cardiovascular Therapeutic Drugs Market Share, By Disease, 2018 & 2026 (%)

Figure 50 Middle East & Africa Cardiovascular Therapeutic Drugs Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 51 Abbott Laboratories: Financials

Figure 52 Pfizer Inc.: Financials

Figure 53 AstraZeneca plc.: Financials

Figure 54 Novartis AG: Financials

Figure 55 Bristol-Myers Squibb Company: Financials

Figure 56 Bayer AG: Financials

Figure 57 Merck & Co., Inc.: Financials

Figure 58 Sanofi: Financials

Figure 59 Boehringer Ingelheim GmbH: Financials

Figure 60 F. Hoffmann-La Roche Ltd: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
step 1We collate your requirements.
step 2Our global research team is put into action.
step 3We deliver, and make sure your endeavour is a success!

Buy This Report